Fuji Pharma Co., Ltd.
Fuji Pharma Co., Ltd. Supplemental Materials for the Fiscal Year Ended September 2026
Published an overview of consolidated results for the fiscal year ended September 2026. Revenue was 59,250 hundred million yen (revised), gross profit margin declined to 39.0%, operating income increased year-over-year, and an impairment loss on available-for-sale securities of 2,000 hundred million yen was recorded as an extraordinary loss. By segment, women's healthcare, biosimilars, and CMO continued to drive growth. The full-year forecast shows the revised projection and differences compared with the prior year.
Key Figures
- Revenue: 59,250 hundred million yen (revised forecast) Specified cumulative results
- Operating Income: 6,355 hundred million yen
- Net Income Attributable to Owners of Parent: 2,831 hundred million yen
AI要約
Overview of Results
Consolidated results for the fiscal year ended September 2026 achieved revenue of 59,250 hundred million yen (compared with the revised forecast), gross profit of 24,321 hundred million yen, and operating income of 6,355 hundred million yen, all increasing year-over-year. Meanwhile, ordinary income was 6,176 hundred million yen and net income was 2,831 hundred million yen, showing slight declines. This was affected by an impairment loss on available-for-sale securities of 2,000 hundred million yen recorded as an extraordinary loss. EBITDA reached 10,562 hundred million yen, and gross profit margin declined to 39.0% against a backdrop of increased expenses including foreign exchange impacts. By segment, women's healthcare, biosimilars, and CMO continued to drive growth.
Medium- to Long-term Outlook and Strategy
All three growth strategies in the medium-term management plan (women's healthcare, biosimilars, and global CMO) are maintaining growth. In the segment revenue breakdown, expansion in women's healthcare and biosimilars continues. The launch status of new drugs and generics and the inclusion of drugs in reimbursement pricing are expected to affect future performance. The full-year forecast reflects the revised level, and attention should be paid to the impacts of foreign exchange and rising raw material costs.
Revenue Trend
Operating Income Trend
Gross Margin Trend
Segment Revenue
Forecast vs Actual Comparison
Fuji Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR